SteadyMed

SteadyMed Ltd. is a specialty pharmaceutical company focused on the development and commercialization of therapeutic product candidates that address the limitations of market-leading products in certain orphan and other well-defined markets.

The lead product candidate is Trevyent, a novel “patch pump” device prefilled with treprostinil for the treatment of pulmonary arterial hypertension. Deerfield participated in its $12 million capital raise which will fund SteadyMed through the regulatory requirements for US and European approval of Trevyent.